An original joint announcement with Photys on 2026-08-13 reports Phase 1 healthy-volunteer dosing of HPB-143/PHT-776. Polymed licensed development and commercialization rights outside Greater China and Southeast Asia to Photys.
2021-07-30 · Pre-Series A (historical completed round disclosure) · RMB 50 million ↗
The company separately announced the launch of a pre-Series A+ round in 2022, without a closing date or amount.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
An original joint announcement with Photys on 2026-08-13 reports Phase 1 healthy-volunteer dosing of HPB-143/PHT-776. Polymed licensed development and commercialization rights outside Greater China and Southeast Asia to Photys.
Program / service
Target / indication
Representative stage
Evidence & scope
HPB-143 / PHT-776
IRAK4; KRAS G12D / EGFR (preclinical or stage unverified) · See individual trial / indication; not individually confirmed in this review
Phase 1
IND / clinical entry disclosed; public human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
This is the same asset as Photys's, not another independent drug. Website projections for KRAS, EGFR, and DAC clinical entry are not actual dosing evidence. HPB-092 is an inhibitor and is excluded from the degradation pipeline.
